Efficacy of cyclooxygenase-2-specific inhibitors

American Journal of Medicine

Volumn 110, Issue 3 SUPPL. 1, 2001, Pages 6-12

  Cannon, Grant W ^a,c   Breedveld, Ferdinand C ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ANALGESIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GASTROINTESTINAL TOXICITY; HUMAN; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0035911009     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(00)00681-1     Document Type: Review

References (30)

1. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
2. Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles
3. Mechanism of action of nonsteroidal anti-inflammatory drugs
4. Mechanism of action of aspirin-like drugs
5. Biology and toxic effects of nonsteroidal anti-inflammatory drugs
6. NSAID associated gastropathy: Incidence and risk factor models
7. Non-steroidal anti-inflammatory drugs and platelet function
8. The discovery and function of COX-2
9. Cyclo-oxygenase isoenzymes
10. COX-2 inhibitors
11. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes
12. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs
13. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor
14. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
15. MK-0966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study
16. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib
17. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
18. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
19. Rofecoxib results in superior clinical response compared to nabumetone in the treatment of osteoarthritis
20. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
21. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomized double-blind comparison
22. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
23. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model
24. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
25. Analgesic efficacy of the cyclooxgenase-2 specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial
26. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial
27. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator trial
28. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans